[1]
|
Early Breast Cancer Trialists’ Collaborative Group, “Effect of Chemotherapy and Hormonal Therapy for Early Breast Cancer on Recurrence and 15-Year Survival: An Overview of the Randomised Trials,” Lancet, Vol. 365, No. 9472, 2005, pp. 1687-1717.
doi:10.1016/S0140-6736(05)66544-0
|
[2]
|
G. Bonadonna, E. Brusamolino, P. Valagussa, A. Rossi, L. Brugnatelli, C. Brambilla, M. De Lena, G. Tancini, E. Bajetta, R. Musumeci and U. Veronesi, “Combination Chemotherapy as an Adjuvant Treatment in Operable Breast Cancer,” The New England Journal of Medicine, Vol. 294, No. 8, 1976, pp. 405-410.
doi:10.1056/NEJM197602192940801
|
[3]
|
G. Bonadonna, A. Moliterni, M. Zambetti, M. G. Dandone, S. Pilotti, L. Gianni and P. Valagussa, “30 Years’ Follow up of Randomised Studies of Adjuvant CMF in Operable Breast Cancer: Cohort Study,” British Medicine Journal, Vol. 330, No. 7485, 2005, pp. 205-206.
doi:10.1136/bmj.38314.622095.8F
|
[4]
|
Early Breast Cancer Trialists Collaborative Group, “Polychemotherapy for Early Breast Cancer: An Overview of Randomised Trials,” Lancet, Vol. 352, No. 9132, 1998, No. 9132, pp. 930-942.
doi:10.1016/S0140-6736(98)03301-7
|
[5]
|
G. Cocconi, “Adjuvant Chemotherapy in Early Breast Cancer: Optimal and Suboptimal Anthracycline Containig Regimens,” Breast Cancer Research and Treatment, Vol. 80, No. 3, 2003, pp. 313-320.
doi:10.1023/A:1024955408785
|
[6]
|
R. B Weiss, D. C.Tormey, F. Holland, V. E. Weinberg, G. Lesnick, M. Perloff, G. Falkson and O. J. Glidewell, “A Randomised Trial of Postoperative Five-versus Three Drug Chemotherapy after Mastectomy; A Cancer and Leukemia Group B (CALGB) Study,” Recent Results Cancer Research, Vol. 80, No. 1, 1982, pp. 170-176.
|
[7]
|
D. C. Tormey, V. E. Weinberg, J. F. Holland, R. B. Weiss, O. J. Glidewell, M. Perloff, G. Falson, H. C. Falkson, P. H. Henry and L. A. Leone, “A Randomised Trial of Five and Three Drug Chemotherapy and Chemo-Immunotherapy in Women with Operable Node Positive Breast Cancer. A CALGB Study,” Journal of Clinical Oncology, Vol. 1, No. 2, 1983, pp. 138-145.
|
[8]
|
L. Gianni, J. Baselga, W, Elemann, V. G. Porta, V. Semi- glazov, A. Lluch, M. Zambetti, D. Sabadell, G. Raab, A. L. Cussac, A. Bozhok, A. Martinez-Agullo, et al., “Phase III Trial Evaluating the Addition of Paclitaxel to Doxorubicin Followed by Cyclo-phosphamide, Methotrexate, and Fluorouracil, as Adjuvant or Primary Systemic Therapy European Cooperative Trial in Operable Breast Cancer,” Journal of Clinical Oncology, Vol. 27, No. 15, 2009, pp. 2474-2481.
doi:10.1200/JCO.2008.19.2567
|
[9]
|
G. Cocconi, G. Bisagni, M. Bacchi, F. Buzzi, R. Canaletti, A. Carpi, G. Ceci, A. Colozza, V. De Lisi and R. Lottici “A Comparison of Continuation versus Late Intensification Followed by Discontinuation of Chemotherapy in Advanced Breast Cancer. A Prospective Randomized Trial of the Italian Oncology Group for Clinical Research (GOIRC),” Annals of Oncology, Vol. 1, No. 1, 1990, pp. 36-44.
|
[10]
|
G. Cocconi, B. Di Blasio, C. Boni, G. Bisagniu, G. Ceci, E. Rondini, M. Bella, F. Leonardi, L. Savoldi, R. Camisa and P. Bruzzi, “Randomized Trial Comparing Cyclophosphamide, Methotrexate, and 5-Fluorouracil (CMF) with Rotational CMF, Epirubicin and Vincristine as Primary Chemotherapy in Operable Breast Cancer,” Cancer, Vol. 95, No. 2, 2002, pp. 228-235.
doi:10.1002/cncr.10678
|
[11]
|
G. Cocconi, B. Di Blasio, C. Boni, G. Bisagni, G. Ceci, E. Rondini, M. Bella, F. Leonardi, L. Savoldi, C. Vallisneri, R. Camisa and P. Bruzzi, “Primary Chemotherapy in Operable Breast Carcinoma Comparing CMF (Cyclophosphamide, Methotreaxate, 5-Fluorouracil) with an Anthracycline Containing Regimen: Short-Term Responses Translated into Long-Term Outcomes,” Annals of On- cology, Vol. 16, No. 9, 2005, pp. 1469-1476.
doi:10.1093/annonc/mdi278
|
[12]
|
A. B. Miller, R. Hoogstraten, M. Staquet and A. Winkler, “Reporting Results of Cancer Treatment,” Cancer, Vol. 47, No. 1, 1981, pp. 207-214.
doi:10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6
|
[13]
|
C. A. Hudis, W. E. Barlow, J. P. Costantino, R. J. Gray, K. I. Pritchard, J. W. Chapman, J. A. Sparano, S. Hunsberger, R. A. Enos, R. D. Gelber and J. O. Zujewski, “Proposal for Standardized Definitions for Efficacy End Points in Adjuvant Breast Cancer Trials: The STEEP System,” Journal of Clinical Oncology, Vol. 25, No. 15, 2007, pp. 2127-2132. doi:10.1200/JCO.2006.10.3523
|
[14]
|
E. L. Kaplan and P. Meier, “Nonparametric Estimation from Incomplete Observations,” Journal of the American Statistical Association, Vol. 53, No. 282, 1958, pp. 457-481. doi:10.2307/2281868
|
[15]
|
D. R. Cox, “The Regression Analysis of Binary Sequences,” Journal of the Royal Statistical Society, Vol. 20, No. 2, 1958, pp. 215-242.
|
[16]
|
J. Cuzick, “Forest Plots and the Interpretation of Subgroups,” Lancet, Vol. 365, No. 9467, 2005, p. 1308.
doi:10.1016/S0140-6736(05)61026-4
|
[17]
|
B. Fisher, A. M. Brown, N. V. Dimitrov, R. Poisson, C. Redmond, R. G. Margolese, D. Bowman, N. Wolmark, D. L. Wickerham, et al., “Two Months of Doxorubicin-Cyclophosphamide with and without Reinduction Therapy Compared with 6 Months of Cyclophosphamide, Methotrexate, and Fluo- rouracil in Positive-Node Breast Cancer Patients with Tamoxifen Non-responsive Tumors: Results from the National Surgical Adjuvant Breast and Bowel Project B-15,” Journal of Clinical Oncology, Vol. 8, No. 9, 1990, pp. 1483-1496.
|
[18]
|
B. Fisher, S. Anderson, Chiu-Tan, N. Wolmark, D. L. Wickerham, E. R. Fisher, N. V. Dimitrov, J. N. Atkins, N. Abramson, S. Merajver, E. H. Romon, C. G. Kardinakl, et al., “Tamoxifen and Chemotherapy for Axillary Node-Negative, Estrogen Receptor-Negative Breast Cancer: Findings from the National Surgical Adjuvant Breast and Bowel Project B-23,” Journal of Clinical Oncology, Vol. 19, No. 4, 2001, pp. 931-942.
|
[19]
|
M. Martin, A. Villar, A. Sole-Calvo, R. Gonzalez, B. Massuti, J. Lizon, C. Camps, A. Carrato, et al., “Doxorubicin in Combination with Fluorouracil and Cyclophosphamide (i.v. FAC Regimen day 1, 21) versus Methotrexate in Combination with Fluorouracil and Cyclophosphamide (i.v. CMF Regimen, day 1, 21) as Adjuvant Chemotherapy for Operable Breast Cancer: A Study of the GEICAM Group,” Annals of Oncology, Vol. 14, No. 6, pp. 833-842.
doi:10.1093/annonc/mdg260
|
[20]
|
H. T. Mouridsen, J. Andersen, M. Andersson, P. Dombernowsky, B. Ejilertsen, C, Rose, P. G. Sorensen, E. Sandberg, K. W. Andersen, M. B. Jensen, N. O. Bengston, J. Bergh and B. Nordenskjold, “Adjuvant Anthracycline in Breast Cancer Improves Outcome in Premenopausal Patients Following Substitution of Methotrexate in the CMF Combination with Epirubicin,” Proceed ASCO, Vol. 18, No. 68, 1999, p. 19.
|
[21]
|
P. Francis, J. Crown, A. Di Leo, M. Buyse, A. Balil, M. Andersson, B. Nordenskjold, I. Lang, R. Jakesz, D. Vorobiof, J. Gutierrez, G. van Hazel, S. Dolci, S. Jamin, B. Bendahmane, R. D. Gelber, M. Castiglione-Gerstsch and M. Piccart-Gebhart, “Adjuvant Chemotherapy with Sequential or Concurrent Anthracycline and Docetaxel: Breast International Group 02-98 Randomized Trial,” Journal of National Cancer Institution, Vol. 100, No. 2, 2008, pp. 121-133. doi:10.1093/jnci/djm287
|
[22]
|
J. M. Albert, A. U. Budzar, R. Guzman, P. K. Allen, E. A. Strom, G. H. Perkins, W. A. Woodward, K. E. Hoffman, W. Tereffe, K. K. Hunt, T. A. Buchholz and G. L. Oh, “Prospective Randomized Trial of 5-Fluorouracil, Doxo-rubicin, and Cyclophosphamide (FAC) versus Paclitaxel and FAC (TFAC) in Patients with Operable Breast Cancer: Impact of Taxane Chemotherapy on Locoregional Control,” Breast Cancer Research and Treatment, Vol. 128, No. 2, 2011, pp. 421-427.
|